Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed ...

Sangamo will regain full rights to giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A, after Pfizer ended ...

Sangamo plans to explore all options to commercialize the Hemophilia A asset.

Richmond: Sangamo Therapeutics, Inc., a genomic medicine company, has announced it will regain development and ...